Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

March 31, 2011

Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL

Albutein 5%

"18 Plasma Exchanges using Albutein 5%:~* three weeks of intensive treatment with two plasma exchanges per week~* six weeks of maintenance treatment with one weekly plasma exchange~* three months of maintenance treatment with one plasma exchange every two weeks"

OTHER

Control

Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)

Trial Locations (4)

20059

Howard University, Washington D.C.

28007

Hospital General Universitario Gregorio Marañon, Madrid

08759

Mid-Atlantic Geriatric/ARC, Whiting

08028

Fundació ACE, Barcelona

All Listed Sponsors
collaborator

Grifols Biologicals, LLC

INDUSTRY

lead

Instituto Grifols, S.A.

INDUSTRY

NCT00742417 - Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid | Biotech Hunter | Biotech Hunter